- Previous Close
0.5590 - Open
0.5590 - Bid 0.5300 x 1000
- Ask 0.5790 x 1000
- Day's Range
0.5206 - 0.5794 - 52 Week Range
0.5206 - 17.1700 - Volume
149,972 - Avg. Volume
142,118 - Market Cap (intraday)
21.188M - Beta (5Y Monthly) 0.40
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.00
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.
www.aeonbiopharma.comRecent News: AEON
View MorePerformance Overview: AEON
Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AEON
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AEON
View MoreValuation Measures
Market Cap
21.19M
Enterprise Value
37.15M
Trailing P/E
--
Forward P/E
1.16
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-597.69%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-305.52M
Diluted EPS (ttm)
-0.1100
Balance Sheet and Cash Flow
Total Cash (mrq)
3.44M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-24.6M